2023-05-09 08:10:56 ET
- Agenus press release ( NASDAQ: AGEN ): Q1 GAAP EPS of -$0.22 misses by $0.01 .
- Revenue of $22.9M (-11.7% Y/Y) misses by $0.63M .
- At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments
- Botensilimab/balstilimab combination data update selected for late-breaking oral session at the ESMO-GI conference in June 2023
- FDA granted Fast Track Designation to the botensilimab/balstilimab combination in colorectal cancer in April 2023
- At a plenary session at SGO, botensilimab/balstilimab combination showed 33% overall response rate in platinum-resistant ovarian cancer patients
- Phase II ACTIVATE trials expected to fully enroll in second half of 2023
- AGEN2373 monotherapy data to be presented at ASCO in June 2023
- Balstilimab/zalifrelimab data in the treatment of sarcoma to be presented at ASCO oral session in June 2023
- Shares +0.63% PM.
For further details see:
Agenus GAAP EPS of -$0.22 misses by $0.01, revenue of $22.9M misses by $0.63M